MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

Abstract

MET has shown significant expression at advanced stages of the disease, as well as for overall survival and cancer-related mortality rates demonstrating to be a valuable marker for poor prognosis in colorectal cancer patients.